Tonix Pharmaceuticals Announces New European Use Patent for TNX-601 GlobeNewswire
Patent Expected to Provide Intellectual Property Protection until 2029 for Use of TNX-601 (Tianeptine Oxalate) for the Treatment of Neurocognitive Dysfunction …
Tonix Pharmaceuticals Announces New European Use Patent for TNX-601 GlobeNewswire
Patent Expected to Provide Intellectual Property Protection until 2029 for Use of TNX-601 (Tianeptine Oxalate) for the Treatment of Neurocognitive Dysfunction …